ALK and non-small cell lung carcinoma: Building upon these findings, the IMpower150 trial (NCT02366143) evaluated a novel quadruplet regimen (atezolizumab+bevacizumab+carboplatin+paclitaxel) vs. standard bevacizumab‐chemotherapy in EGFR/ALK wild‐type nonsquamous NSCLC [32].